Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 11 de 11
Filtrer
1.
Haematologica ; 81(1): 8-14, 1996.
Article de Anglais | MEDLINE | ID: mdl-8900846

RÉSUMÉ

PATIENTS AND METHODS: Ninety-five patients with previously untreated, advanced or unfavorably presenting Hodgkin's disease were recruited in ten centers. Twenty-five patients with stage II-A-bulky disease received four courses of EBVD (epirubicin, bleomycin, vinblastine, dacarbazine) plus involved field radiotherapy (Group 1); 24 patients in stage I-B, II-B and III-A received 6 courses of EBVD (11 of them also received radiotherapy on bulky localizations (Group 2); 46 patients in stage III-AS > or = 3 nodes, III-B and IV received MOPP/EBVD 4 + 4 courses (Group 3). RESULTS: Eighty patients (84%) achieved CR, eight patients (8%) a PR, five patients did not respond and two progressed during therapy. CRs were achieved by 23/25 patients (92%) in Group 1, 21/24 (87%) in Group 2 and 36/46 (78%) in Group 3. The mean duration of follow-up was 33.3 months (range 5-69). There were three deaths from directly treatment-related causes. Twelve patients suffered chronic toxicity, including six who suffered lung toxicity and two who developed secondary myelodysplasia. CONCLUSIONS: The results achieved in this co-operative study are similar to those reported by most single-Institution trials and those with adriamycin-containing regimens. Long-term toxicity deserves careful consideration.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Maladie de Hodgkin/thérapie , Adolescent , Adulte , Sujet âgé , Association thérapeutique , Études de suivi , Maladie de Hodgkin/traitement médicamenteux , Maladie de Hodgkin/radiothérapie , Humains , Chlorméthine/usage thérapeutique , Adulte d'âge moyen , Prednisone/usage thérapeutique , Procarbazine/usage thérapeutique , Vincristine/usage thérapeutique
2.
Tumori ; 81(6): 410-3, 1995.
Article de Anglais | MEDLINE | ID: mdl-8804465

RÉSUMÉ

AIM: The occurrence of unilateral involvement in bilateral bone marrow trephine biopsies in non-Hodgkin's lymphomas (NHL) at disease onset (10-20% of cases) has been reported since the early 70s. Therefore, although these studies were based on small series, the use of bilateral bone marrow biopsies has become the rule. However, the clinical value of this procedure has never been clearly established. The aim of the present study was to ascertain the true value of bilateral bone marrow biopsy in the staging of NHL. STUDY DESIGN: We examined 368 cases of NHL (A-H according to the Working Formulation) (WF), without leukemic involvement of the peripheral blood, in order to evaluate: 1) the incidence of unilateral bone marrow involvement; 2) the percentage of patients who, as a result of unilateral bone marrow involvement, changed from stages I-II to stage IV; 3) assessment of response to therapy for patients with both bilateral or unilateral bone marrow involvement. RESULTS: In the A-C NHL groups of WF there was a unilateral bone marrow involvement of 8.8%. Overall, bone marrow involvement induced a change from clinical stages I-II to stage IV in 5.6% of cases, a figure which would correspond to a false negative rate of 2.8%, if unilateral bone marrow biopsy was performed. In the D-F and G, H groups of WF, unilateral involvement was 10.1% and 8.5% respectively; the change in stage from I-II to IV by unilateral bone marrow involvement respectively amounted to 1.4% and 2.8%, which correspond to respective false negative rates of 0.7% and 1.4%. CONCLUSIONS: On the basis of these results and of the present therapeutic strategies, we propose: bilateral bone marrow biopsy for clinical stages I-II of all NHL; no bone marrow biopsy at disease onset for clinical stages III and IV of A to H histologic subtypes of the WF; unilateral bone marrow biopsy (A-C subtypes of the WF) or bilateral (D-H of the WF), after the regression of extramedullary localizations.


Sujet(s)
Biopsie/méthodes , Moelle osseuse/anatomopathologie , Lymphome malin non hodgkinien/anatomopathologie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Humains , Lymphome malin non hodgkinien/traitement médicamenteux , Stadification tumorale , Études rétrospectives , Résultat thérapeutique
3.
Minerva Urol Nefrol ; 44(4): 249-51, 1992.
Article de Italien | MEDLINE | ID: mdl-1299004

RÉSUMÉ

Stage IV disseminated non-Hodgkin lymphomas show kidney involvement with frequency; on the contrary, primary kidney lymphoma, as the sole presenting feature, is a very rare disease. Non-Hodgkin histological pattern, atypical symptoms, marked discrepancy between parenchymal involvement and impairment of renal function are the main features of this tumor. A case-report of a primary kidney non-Hodgkin lymphoma will be described; a short review of literature on this subject will be discussed.


Sujet(s)
Tumeurs du rein/anatomopathologie , Leucémie chronique lymphocytaire à cellules B/anatomopathologie , Lymphome malin non hodgkinien/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Association thérapeutique , Femelle , Humains , Tumeurs du rein/diagnostic , Tumeurs du rein/thérapie , Leucémie chronique lymphocytaire à cellules B/thérapie , Lymphome malin non hodgkinien/diagnostic , Lymphome malin non hodgkinien/thérapie , Néphrectomie
4.
Minerva Med ; 79(11): 961-4, 1988 Nov.
Article de Italien | MEDLINE | ID: mdl-3200473

RÉSUMÉ

Among the 984 patients suffering from thyroid pathology observed in our Department between 1956 and 1964, we took into consideration the 184 patients who having been diagnosed as having a normally functioning goitre, were not given any treatment. We chose 88 patients living in our region, under 60 years old: 55 of these were included in our study. The long period involved--30 years--allowed us to check the natural course of this pathology, which was shown to be totally benign as well as frequent, and unconnected with other pathologies. Only in one case, at a distance of 20 years, did a neoplasia arise. The evaluation of the results justifies a decision of non-intervention, while recognising the paramount importance of a correct diagnosis, already possible with the diagnostic instruments then available.


Sujet(s)
Goitre nodulaire , Femelle , Études de suivi , Goitre nodulaire/diagnostic , Goitre nodulaire/thérapie , Humains , Mâle , Adulte d'âge moyen , Pronostic , Facteurs temps
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...